Your browser is no longer supported. Please, upgrade your browser.
Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.09 Insider Own0.30% Shs Outstand31.23M Perf Week13.00%
Market Cap833.22M Forward P/E- EPS next Y-3.24 Insider Trans2.32% Shs Float30.58M Perf Month16.56%
Income-93.70M PEG- EPS next Q-0.95 Inst Own- Short Float20.51% Perf Quarter32.34%
Sales- P/S- EPS this Y-31.90% Inst Trans10.48% Short Ratio11.78 Perf Half Y1.64%
Book/sh6.39 P/B4.18 EPS next Y12.40% ROA-38.20% Target Price35.75 Perf Year53.69%
Cash/sh11.52 P/C2.32 EPS next 5Y- ROE-53.90% 52W Range15.93 - 29.41 Perf YTD40.27%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-11.95% Beta1.14
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low62.55% ATR1.05
Employees95 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)58.96 Volatility4.04% 4.86%
OptionableYes Debt/Eq0.79 EPS Q/Q-45.00% Profit Margin- Rel Volume0.76 Prev Close26.68
ShortableYes LT Debt/Eq0.74 EarningsAug 08 AMC Payout- Avg Volume532.21K Price25.90
Recom1.70 SMA205.68% SMA509.75% SMA20021.61% Volume314,728 Change-2.94%
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Sep-19-17 08:36AM  Implied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options Zacks
Sep-07-17 07:30AM  Flexion Therapeutics to Present Data on Zilretta (FX006) at PAINWeek 2017 GlobeNewswire
Aug-30-17 07:30AM  Flexion Therapeutics to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-25-17 01:30PM  'Date' These Potential Biotech Winners TheStreet.com
Aug-13-17 07:26AM  Edited Transcript of FLXN earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 11:57PM  Flexion Therapeutics reports 2Q loss Associated Press
04:05PM  Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
11:10AM  Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 02:06PM  Why Flexion Therapeutics Shares Shot 12.8% Higher in July Motley Fool
Aug-02-17 01:54PM  3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic Motley Fool
08:15AM  3 Biotech Stocks With Big News Coming Motley Fool
Aug-01-17 07:30AM  Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jul-31-17 10:07AM  3 Hot Healthcare Stocks Under $30 Motley Fool -5.39%
Jul-18-17 09:30AM  The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics Zacks
Jul-17-17 09:26AM  4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings Zacks
Jul-10-17 09:25AM  Flexion Therapeutics to Hold Investor & Analyst Day Today GlobeNewswire
Jul-06-17 09:00PM  Why Flexion Therapeutics Rallied 18% in June Motley Fool
Jul-05-17 04:27PM  Biotechs Gained $1.7 Billion Last Week Can They Keep Going? Investor's Business Daily +5.88%
Jul-03-17 07:30AM  Flexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017 GlobeNewswire
Jun-28-17 07:30AM  Flexion Therapeutics Announces Appointment of Mark Levine as General Counsel GlobeNewswire
Jun-23-17 09:00AM  Flexion Therapeutics Named One of Boston Business Journals Best Places to Work GlobeNewswire
Jun-10-17 01:00PM  Flexion Therapeutics to Present Data on Zilretta (FX006) at the American Diabetes Associations 77th Scientific Sessions GlobeNewswire
May-23-17 01:47PM  Flexion CEO on developing an alternative to opioids CNBC Videos
May-22-17 07:30AM  Flexion to Present New Cost-Effectiveness Data on Zilretta (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting GlobeNewswire +8.91%
May-18-17 07:30AM  Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association's 77th Scientific Sessions GlobeNewswire
May-10-17 08:50PM  Another top executive at Sanofi Genzyme leaves company American City Business Journals
May-05-17 04:44PM  Edited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 06:33PM  Flexion Therapeutics reports 1Q loss Associated Press
04:01PM  Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
09:45AM  Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call Accesswire
May-01-17 07:30AM  Flexion Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-28-17 07:30AM  Flexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International 2017 World Congress GlobeNewswire
Apr-26-17 07:04PM  Flexion Therapeutics Announces Pricing of $175 Million 3.375% Convertible Senior Notes due 2024 GlobeNewswire -20.65%
11:39AM  Why Flexion Therapeutics Inc. Stock Is Tanking Motley Fool
09:27AM  Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka TheStreet.com
Apr-25-17 04:01PM  Flexion Therapeutics Announces Proposed Convertible Senior Notes Offering GlobeNewswire
07:30AM  Flexion Therapeutics to Report First-Quarter 2017 Financial Results on May 4, 2017 GlobeNewswire
Apr-19-17 12:25PM  Why Flexion Therapeutics' New Pain Drug Could Be a Game-Changer Motley Fool
Apr-18-17 07:24AM  Can Drugmakers Cure the Opioid Crisis? Motley Fool
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com +6.96%
Apr-07-17 12:40PM  Sanofi Genzyme exec jumps to Flexion amid buyout rumors American City Business Journals
10:42AM  Sanofi Buying Flexion: A Smart Move? Motley Fool
07:30AM  Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer GlobeNewswire
Apr-04-17 07:30AM  Flexion Therapeutics Announces Issuance of Two New Patents Further Strengthening Intellectual Property Protection (IP) for Zilretta (FX006) GlobeNewswire
Mar-31-17 05:03PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-30-17 04:42PM  3 Revolutionary Drugs for Chronic Pain Motley Fool
Mar-28-17 09:00AM  Flexion Therapeutics to Present at Needham & Companys 16th Annual Healthcare Conference GlobeNewswire -6.08%
Mar-26-17 02:00PM  How I'd Play Biotech Buyout Rumors TheStreet.com
Mar-24-17 04:19PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low? Investor's Business Daily
09:30AM  Advances in Healthcare Technology and Osteoarthritis Drug Therapies Propel Two Healthcare Stocks Accesswire
Mar-23-17 05:36PM  Did Sanofi Just Bag This Biotech For $1 Billion? Investor's Business Daily +33.38%
04:36PM  Here's Why Flexion Therapeutics Inc. Skyrocketed Today Motley Fool
03:37PM  Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout Zacks
01:47PM  Flexion tops $800M in market cap on Sanofi buyout rumor at bizjournals.com
11:25AM  Sanofi Said to Be Near $1 Billion Deal for Flexion
Mar-16-17 01:04PM  FLEXION THERAPEUTICS INC Financials
Mar-10-17 08:43PM  Edited Transcript of FLXN earnings conference call or presentation 9-Mar-17 9:30pm GMT
05:01PM  FLEXION THERAPEUTICS INC Files SEC form 10-K, Annual Report
Mar-09-17 04:17PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr
04:01PM  Flexion Reports Year-End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Flexion Therapeutics Inc Earnings Release - After Market Close
Mar-03-17 09:00AM  Flexion Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Mar-02-17 10:42AM  Top Biotech Stocks With FDA Decisions in 2017 at Motley Fool
09:00AM  Flexion Therapeutics to Report Year-End 2016 Financial Results on March 9, 2017 GlobeNewswire
Feb-23-17 07:30AM  Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta (FX006) in Patients with Osteoarthritis of the Knee GlobeNewswire
Feb-15-17 09:00AM  Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-07-17 07:30AM  Flexion Therapeutics Announces New Drug Application for Zilretta (FX006) Accepted by U.S. Food and Drug Administration GlobeNewswire
Dec-29-16 12:03PM  Todd Hagopian's Top Recommendations For 2017 at Forbes
Dec-22-16 07:04AM  Coverage initiated on Flexion Therapeutics by Raymond James
Dec-14-16 12:33AM  Should You Avoid Flexion Therapeutics Inc (FLXN)? at Insider Monkey
Dec-12-16 08:21AM  3 Drugs Heading to the FDA Soon at Motley Fool
07:20AM  Fast-growing Burlington biotech Flexion files for approval of lead drug at bizjournals.com
07:00AM  Flexion Therapeutics Submits New Drug Application for Zilretta to Treat Knee Osteoarthritis Pain GlobeNewswire
Dec-09-16 09:00AM  Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-02-16 02:34PM  Should You Buy DHI Group Inc (DHX)? at Insider Monkey +5.80%
05:50AM  Hedge Funds Are Betting On Casella Waste Systems Inc. (CWST) at Insider Monkey
Nov-29-16 08:17AM  2 Red-Hot Biotechs to Buy Ahead of FDA Decisions at Motley Fool
Nov-28-16 02:21PM  Flexion Therapeutics, Inc. :FLXN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-18-16 04:07PM  FLEXION THERAPEUTICS INC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits
Nov-17-16 03:34PM  Can Flexion Therapeutics Add Some Muscle to Your Portfolio? at Motley Fool
Nov-16-16 04:44PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -10.79%
12:55PM  Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL BioPharma Inc Are Tanking Today at Motley Fool
09:00AM  Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-15-16 04:01PM  Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-14-16 06:20AM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-11-16 09:00AM  Flexion Therapeutics Announces Presentation of Phase 3 Data Demonstrating that Extended-Release Zilretta Achieves Clinically Significant Improvement of Pain, Stiffness and Function in Patients with Osteoarthritis of the Knee GlobeNewswire
Nov-08-16 05:34PM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-16 9:30pm GMT
Nov-07-16 04:48PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:47PM  Flexion Therapeutics reports 3Q loss
04:01PM  Flexion Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 Flexion Therapeutics Inc Earnings Release - After Market Close
Nov-03-16 08:30AM  Flexion Therapeutics Announces that Analysis from Phase 3 Clinical Trial of Zilretta for Osteoarthritis of the Knee to be presented at AAHKS GlobeNewswire -8.63%
Nov-01-16 02:25PM  Trial suggests Flexions knee injection may be safer for diabetes patients at bizjournals.com
07:00AM  Flexion Therapeutics Reports Primary Endpoint Met in Clinical Trial Evaluating Investigational Drug Candidate Zilretta in Type 2 Diabetes Patients with Knee Osteoarthritis GlobeNewswire
Oct-28-16 08:30AM  Flexion Therapeutics to Report Third-Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-13-16 03:00PM  The Case For Flexion To Double By Mid-2017 at Forbes
Sep-29-16 08:30AM  Flexion Therapeutics Announces Appointment of John Magee as Vice President of Sales GlobeNewswire
Sep-21-16 11:01AM  3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions at Motley Fool
Sep-14-16 04:17PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:30AM  Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors GlobeNewswire
Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Deniz YamoChief Medical OfficerSep 05Buy24.201,00024,2009,000Sep 15 05:12 PM
Deniz YamoChief Medical OfficerSep 01Buy24.153,00072,4508,000Sep 15 05:12 PM
Deniz YamoChief Medical OfficerAug 31Buy25.401,37534,9255,000Sep 15 05:12 PM
Stejbach MarkDirectorJun 16Buy17.021,58026,8881,580Jun 20 04:24 PM
COLELLA SAMUEL DDirectorJun 05Buy17.015,00085,0485,000Jun 06 06:49 PM
Clayman Michael D.President and CEOJun 05Buy17.235,00086,15220,146Jun 06 06:47 PM
Bodick NeilChief Medical OfficerMay 15Sale18.956,830129,44839,107May 17 04:15 PM
Bodick NeilChief Medical OfficerApr 17Sale28.235,000141,13245,937Apr 18 07:45 PM
DRISCOLL FREDERICK WChief Financial OfficerMar 23Option Exercise7.893,00023,65810,777Mar 24 04:24 PM
DRISCOLL FREDERICK WChief Financial OfficerMar 23Sale23.003,00069,0007,777Mar 24 04:24 PM
Bodick NeilChief Medical OfficerMar 17Sale20.415,000102,03950,937Mar 20 07:42 PM
DRISCOLL FREDERICK WChief Financial OfficerFeb 28Option Exercise7.8930,000236,58341,211Mar 02 04:56 PM
DRISCOLL FREDERICK WChief Financial OfficerFeb 28Sale19.9733,434667,6797,777Mar 02 04:56 PM
Bodick NeilChief Medical OfficerFeb 24Sale19.155,00095,75855,937Feb 27 04:17 PM
Bodick NeilChief Medical OfficerJan 20Sale18.355,00091,74760,937Jan 23 07:10 PM
Bodick NeilChief Medical OfficerDec 21Sale18.4610,000184,62865,937Dec 22 04:40 PM
COLELLA SAMUEL DDirectorDec 01Buy16.3810,000163,80743,333Dec 05 02:40 PM
Clayman Michael D.President and CEONov 23Buy18.411,66730,68830,721Nov 23 08:17 PM
Clayman Michael D.President and CEONov 22Buy17.951,66629,90029,054Nov 23 08:35 AM
Clayman Michael D.President and CEONov 21Buy17.901,66629,82727,388Nov 22 02:28 PM
COLELLA SAMUEL DDirectorNov 21Buy18.0033,333599,99433,333Nov 22 06:40 PM